Leqvio®

Understanding Leqvio® 

Leqvio® (inclisiran) is an FDA-approved medication used to lower low-density lipoprotein cholesterol (LDL-C) in patients at risk for cardiovascular disease. It is the first small interfering RNA (siRNA) therapy designed to target the production of the PCSK9 protein, thereby reducing LDL cholesterol levels. This innovative mechanism supports effective cholesterol management and helps lower the risk of cardiovascular events.

How Leqvio® Works:

• Targets PCSK9 protein production to enhance LDL-C clearance
• Reduces LDL cholesterol levels in patients at high cardiovascular risk
• Provides long-term cholesterol management with an infrequent dosing schedule

FDA Approval:

• Leqvio® (inclisiran): Approved on December 22, 2021

For more information, please visit the Leqvio® patient website and speak with your healthcare provider to determine if Leqvio® is the right treatment option for you.